Mark D Erion Selected Research

Mark D Erion Research Topics

Disease

11	Type 2 Diabetes Mellitus (MODY) 12/2016 - 05/2005
6	Hypoglycemia (Reactive Hypoglycemia) 01/2022 - 05/2005
5	Hyperglycemia 01/2019 - 06/2006
3	Insulin Resistance 01/2019 - 01/2011
3	Hepatocellular Carcinoma (Hepatoma) 10/2009 - 02/2005
3	Hepatitis B 02/2008 - 01/2005
2	Metabolic Diseases (Metabolic Disease) 01/2019 - 12/2007
2	Vomiting 01/2019 - 12/2005
2	Weight Loss (Weight Reduction) 01/2019 - 01/2012
2	Heart Diseases (Heart Disease) 01/2019 - 11/2016
2	Cardiomegaly (Heart Hypertrophy) 01/2017 - 11/2016
2	Neoplasms (Cancer) 10/2009 - 12/2006
2	Infections 08/2007 - 01/2005
1	Hyperinsulinism (Hyperinsulinemia) 01/2019
1	Diabetes Mellitus 11/2018
1	Dyslipidemias (Dyslipidemia) 01/2018
1	Inflammation (Inflammations) 11/2016
1	Cysts 11/2016
1	Wolff-Parkinson-White Syndrome (Wolf-Parkinson-White Syndrome) 11/2016
1	Weight Gain 01/2011
1	Hyperlipidemias (Hyperlipidemia) 12/2010
1	Non-alcoholic Fatty Liver Disease 02/2009
1	Liver Cirrhosis (Hepatic Cirrhosis) 02/2009
1	Hypercholesterolemia 11/2008
1	Body Weight (Weight, Body) 09/2007
1	Hepatitis 02/2006
1	Pain (Aches) 12/2005
1	Ataxia (Dyssynergia) 12/2005
1	Liver Diseases (Liver Disease) 02/2005
1	Hepatitis C 02/2005
1	Chronic Hepatitis B 11/2004
1	Edema (Dropsy) 10/2003
1	Ischemia 09/2003

Drug/Important Bio-Agent (IBA)

13	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 05/2005
11	ProdrugsIBA 12/2010 - 11/2004
6	Insulin (Novolin)FDA Link 01/2022 - 01/2011
5	Pharmaceutical PreparationsIBA 12/2010 - 05/2005
4	GlycogenIBA 01/2019 - 06/2006
4	Blood Glucose (Blood Sugar)IBA 11/2018 - 07/2007
4	NucleosidesIBA 10/2009 - 10/2003
3	Fructose-BisphosphataseIBA 01/2011 - 07/2007
3	N,N'- ((5- (2- amino- 5- (2- methylpropyl)- 4- thiazolyl)- 2- furanyl)phosphinylidene)bis(alanine) diethyl esterIBA 01/2011 - 05/2005
3	2- ((3,5- dimethyl- 4- (4'- hydroxy- 3'- isopropylbenzyl)phenoxy)methyl)- 4- (3- chlorophenyl)- 2- oxido(1,3,2)dioxaphosphonaneIBA 02/2009 - 09/2007
2	Hypoglycemic Agents (Hypoglycemics)IBA 01/2022 - 01/2011
2	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2019 - 01/2012
2	EnzymesIBA 01/2011 - 12/2007
2	Lactic Acid (Lactate)FDA LinkGeneric 01/2011 - 05/2005
2	LipidsIBA 01/2011 - 11/2008
2	adefovir dipivoxil (Hepsera)FDA Link 02/2008 - 11/2004
2	Triglycerides (Triacylglycerol)IBA 09/2007 - 05/2005
2	FructoseIBA 06/2006 - 05/2005
2	Adenosine KinaseIBA 12/2005 - 10/2003
1	Insulin ReceptorIBA 01/2022
1	Appetite Depressants (Anorectics)IBA 01/2019
1	Liraglutide FDA Link 01/2019
1	CeramidesIBA 01/2019
1	Anti-Obesity Agents (Antiobesity Drugs)IBA 01/2019
1	LeptinIBA 01/2019
1	Glucagon-Like Peptide-1 ReceptorIBA 01/2019
1	Fatty Acids (Saturated Fatty Acids)IBA 01/2018
1	MK-8722IBA 01/2017
1	AMP-Activated Protein KinasesIBA 11/2016
1	N- ((4- (1- (3- (3,5- dichlorophenyl)- 5- (6- methoxynaphthalen- 2- yl)- 1H- pyrazol- 1- yl)ethyl)phenyl)carbonyl)- beta- alanineIBA 11/2015
1	Glucagon (Glukagon)FDA Link 11/2015
1	Peptides (Polypeptides)IBA 01/2012
1	Glucagon Receptors (Glucagon Receptor)IBA 01/2012
1	Organophosphonates (Phosphonates)IBA 12/2010
1	Cytarabine (Cytosar-U)FDA LinkGeneric 10/2009
1	fludarabineIBA 10/2009
1	triphosphoric acid (triphosphate)IBA 10/2009
1	4- amino- 1- (5- O- (2- oxo- 4- (4- pyridyl)- 1,3,2- dioxaphosphorinan- 2- yl)arabinofuranosyl)- 2(1H)- pyrimidinoneIBA 10/2009
1	Nonesterified Fatty Acids (NEFA)IBA 02/2009
1	Transaminases (Aminotransferases)IBA 02/2009
1	Thyroid HormonesIBA 02/2009
1	LDL CholesterolIBA 02/2009
1	Thyroid Hormone Receptors (Thyroid Hormone Receptor)IBA 02/2009
1	pradefovirIBA 02/2008
1	adefovirIBA 02/2008
1	Adenosine Monophosphate (AMP)IBA 12/2007
1	CholesterolIBA 09/2007
1	KB 141IBA 09/2007
1	2'-C-methyladenosineIBA 08/2007
1	NucleotidesIBA 02/2006
1	BradykininIBA 12/2005
1	pyrimidineIBA 12/2005
1	Formaldehyde (Formol)FDA Link 12/2005
1	Antiviral Agents (Antivirals)IBA 01/2005
1	Lamivudine (Epivir)FDA Link 01/2005
1	EsterasesIBA 11/2004
1	Dihydrotachysterol (AT 10)IBA 10/2003
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 10/2003
1	CarrageenanIBA 10/2003
1	AutacoidsIBA 09/2003
1	Adenosine (Adenocard)FDA LinkGeneric 09/2003

Therapy/Procedure

4	Therapeutics 11/2018 - 11/2004
1	Injections 01/2022
1	Intraperitoneal Injections 12/2016
1	Glycemic Control 12/2016
1	Intravenous Administration 01/2010
1	Aftercare (After-Treatment) 02/2009